A scoping review of the role of managed entry agreements in upcoming drugs for amyotrophic lateral sclerosis: learning from the case of spinal muscular atrophy-Reference-Cited by-同舟云学术

A scoping review of the role of managed entry agreements in upcoming drugs for amyotrophic lateral sclerosis: learning from the case of spinal muscular atrophy

Published:2024-09-10 Issue: Volume: Page:1-10
ISSN:2167-8421
Container-title:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
language:en
Short-container-title:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Author:

García-Parra Beliu¹^ORCID,Guiu Josep M.²,Povedano MÓnica¹³,Modamio Pilar²

Affiliation:

1. Clinical Neurophysiology Section – Neurology Service, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain

2. Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Clinical Pharmacy and Pharmaceutical Care Unit, University of Barcelona, Barcelona, Spain, and

3. Motor Neuron Diseases Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21678421.2024.2400522

Reference60 articles.

1. Prior TW, Leach ME, Finanger E. Spinal muscular atrophy. In: Adam MP, Feldman J, Mirzaa GM, et al. eds. GeneReviews®. Seattle, WA: University of Washington, Seattle; 2000.

2. Cross-disease comparison of amyotrophic lateral sclerosis and spinal muscular atrophy reveals conservation of selective vulnerability but differential neuromuscular junction pathology

3. Amyotrophic lateral sclerosis: a clinical review

4. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management

5. Updates in clinical data for FDA-approved disease-modifying therapies for spinal muscular atrophy;Bisaccia E.;Am J Manag Care,2021